Overview
flowchart TD
companies_shanghai_neurotech["Shanghai NeuroTech"]
style companies_shanghai_neurotech fill:#4fc3f7,stroke:#333,color:#000
companies_shanghai_n_0["Company Profile"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_0
style companies_shanghai_n_0 fill:#81c784,stroke:#333,color:#000
companies_shanghai_n_1["Technology Platform"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_1
style companies_shanghai_n_1 fill:#ef5350,stroke:#333,color:#000
companies_shanghai_n_2["AAV Gene Therapy Vectors"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_2
style companies_shanghai_n_2 fill:#ffd54f,stroke:#333,color:#000
companies_shanghai_n_3["Cell Therapy Platform"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_3
style companies_shanghai_n_3 fill:#ce93d8,stroke:#333,color:#000
companies_shanghai_n_4["RNA-Targeted Therapeutics"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_4
style companies_shanghai_n_4 fill:#4fc3f7,stroke:#333,color:#000
companies_shanghai_n_5["Pipeline"]
companies_shanghai_neurotech -->|"includes"| companies_shanghai_n_5
style companies_shanghai_n_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Shanghai NeuroTech is a Chinese biotechnology company pioneering gene therapy and cell therapy approaches for neurodegenerative diseases. Founded in 2017 and headquartered in Shanghai, the company has developed a comprehensive platform for AAV-based gene delivery, iPSC-derived cell therapies, and RNA-targeted approaches for Parkinson's disease, Alzheimer's disease, and related disorders.
The company's name reflects its Shanghai origins and focus on neurotechnology—combining the city's designation with its therapeutic area. Shanghai NeuroTech operates from state-of-the-art facilities in the Zhangjiang Science City, one of China's premier biopharmaceutical clusters["xie2023"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Shanghai, China |
| Founded | 2017 |
| Focus | AAV gene therapy, cell therapy |
| Employees | ~85 (as of 2024) |
| Stage | IND-enabling |
Shanghai NeuroTech benefits from its strategic location in the Yangtze River Delta, with access to leading academic medical centers including Fudan University Huashan Hospital, Shanghai Jiao Tong University, and the Chinese Academy of Sciences Institute of Neuroscience.
AAV Gene Therapy Vectors
Shanghai NeuroTech has invested heavily in AAV (adeno-associated virus) vector development, creating novel capsids with enhanced brain transduction properties:
Proprietary capsid library: The company has generated a library of novel AAV capsids with mutations in surface residues, selecting for variants with enhanced neuronal and astrocyte tropism following intravenous delivery.
Brain-penetrant designs: Through iterative engineering, Shanghai NeuroTech has developed capsids capable of crossing the blood-brain barrier (BBB) following systemic administration, eliminating the need for direct brain injection[@hudry2023].
Cell-type specificity: Promoter engineering enables cell-type specific expression—neurons (synapsin promoter), astrocytes (GFAP promoter), or microglia (CD68 promoter).The company's lead capsid variant demonstrates 15-20x improvement in brain delivery compared to AAV9 in non-human primates, supporting the translation of its gene therapy programs[@mcdonnell2023].
Beyond gene therapy, Shanghai NeuroTech maintains a cell therapy platform:
iPSC-derived dopamine neurons: Induced pluripotent stem cells differentiated into dopaminergic neurons for cell replacement therapy in Parkinson's disease
Allogeneic and autologous approaches: Both off-the-shelf and patient-specific options
Gene-edited iPSCs: CRISPR-corrected lines for genetic forms of PDRNA-Targeted Therapeutics
The company is developing RNA-based approaches:
- Antisense oligonucleotides: Targeting APP mRNA for Alzheimer's disease
- siRNA: Knockdown of alpha-synuclein for PD
- miRNA sponges: Modulation of regulatory RNAs
Pipeline
SNT-001: AAV-GBA for Parkinson's Disease
SNT-001 is Shanghai NeuroTech's lead clinical candidate—an AAV gene therapy delivering the glucocerebrosidase (GBA) gene.
Rationale
GBA (glucocerebrosidase) mutations are among the most common genetic risk factors for Parkinson's disease. GBA deficiency leads to accumulation of glucosylceramide, which promotes alpha-synuclein aggregation and contributes to dopaminergic neuron loss[@pchelina2017].
SNT-001 delivers a functional GBA gene to restore enzymatic activity, potentially:
- Reduce glucosylceramide accumulation
- Decrease alpha-synuclein pathology
- Protect dopaminergic neurons
Development Status
- Discovery: Completed
- Preclinical: IND-enabling studies ongoing
- IND submission: Projected 2026
Preclinical Results
- Significant increase in brain GBA activity in non-human primates
- Reduction in glucosylceramide in target brain regions
- Improved motor function in GBA-deficient mouse models
- Favorable safety profile in GLP toxicology
SNT-002: AAV-Alpha-Synuclein RNAi
SNT-002 uses AAV-mediated RNAi to reduce alpha-synuclein expression.
Mechanism
SNT-002 delivers an shRNA targeting the SNCA gene (encoding alpha-synuclein), reducing protein expression and potentially preventing aggregation.
Development Status
- Discovery: Completed
- Lead optimization: Ongoing
- IND submission: Projected 2027
SNT-101: AAV-BDNF for Alzheimer's Disease
SNT-101 delivers brain-derived neurotrophic factor (BDNF) for Alzheimer's disease.
Rationale
BDNF is a critical neurotrophin that supports neuronal survival, synaptic plasticity, and cognitive function—all of which decline in AD[@day2023]. Gene therapy provides sustained BDNF expression from a single administration.
Development Status
- Discovery: Active
- IND submission: Projected 2028
Additional Programs
Shanghai NeuroTech maintains discovery programs in:
- LRRK2-targeted gene therapy for PD
- GIGYF2 gene therapy
- Autophagy enhancement approaches
Research Collaborations
Academic Partnerships
- Fudan University: Neuroscience research, iPSC derivation, and clinical translation
- Chinese Academy of Sciences: AAV capsid engineering and neuroscience
- Shanghai Institute of Materia Medica: Drug discovery and pharmacology
- Shanghai Jiao Tong University: Animal models and behavioral testing
Industry Collaborations
- WuXi Biologics: GMP vector manufacturing
- Oxford Biomedica: Process development
- Thermo Fisher Scientific: Reagents and analytics
- Charles River Laboratories: GLP toxicology
International Partnerships
Shanghai NeuroTech has established:
- US subsidiary: For FDA engagement and clinical development
- European research collaborations: With leading EU universities
- Japan regulatory strategy: PMDA consultations planned
Manufacturing
The company has established internal GMP manufacturing capabilities:
- AAV production: Triple transfection in HEK293 cells
- Purification: Chromatography-based purification (affinity, ion exchange, gradient)
- Fill-finish: Aseptic fill for clinical supply
- Scale: Current capacity: 50L; expansion to 200L planned for 2025
Quality control includes:
- Potency assays (transduction, expression)
- Purity (SDS-PAGE, AUC)
- Identity (sequencing, capsid typing)
- Safety (sterility, endotoxin, mycoplasma)
Competitive Landscape
Shanghai NeuroTech competes in the AAV gene therapy space for CNS disorders:
| Company | Product | Indication | Status |
|---------|---------|------------|--------|
| Voyager Therapeutics | VY-AADC01 | Parkinson's disease | Phase I/II |
| Prevail Therapeutics | PR001 | Parkinson's disease (GBA) | Phase I/II |
| Roche/Chiesi | AAV-GDNF | Parkinson's disease | Phase II |
| Neurocrine/Biogen | VY-90001 | Parkinson's disease | Phase I |
| Shanghai NeuroTech | SNT-001 | Parkinson's disease (GBA) | IND-enabling |
Shanghai NeuroTech differentiates through:
- Superior capsid technology (BBB-penetrant IV delivery)
- Comprehensive platform (gene therapy + cell therapy)
- Strong position in Chinese market
Funding and Financial History
| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Seed | 2017 | $3M | Zhangjiang VC |
| Series A | 2019 | $12M | Qiming Venture, China Bio |
| Series B | 2021 | $28M | GL Capital, Qiming |
| Series C | 2023 | $35M | Hillhouse Capital, CCB Capital |
Total raised: $78M
Future Directions
Shanghai NeuroTech's long-term strategy includes:
Clinical development: Advance SNT-001 through IND and into clinical trials
Platform expansion: Continue development of AAV capsid library
Cell therapy advancement: Move iPSC-dopamine neuron program toward clinic
Geographic expansion: Establish clinical operations in US and EU
Business development: Seek partnerships for global commercializationSee Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Gene Therapy for Neurodegeneration](/treatments/gene-therapy)
- [AAV Vector Biology](/mechanisms/aav-vector-biology)
- [GBA Gene](/genes/gba)
- [Alpha-Synuclein Pathology](/proteins/alpha-synuclein)
- [Chinese Biotechnology Companies](/companies/chinese-biotech-overview)
References
[Shanghai NeuroTech Corporate Materials (2024)](https://www.shneurotech.com)
[Kalia LV, Lang AE, Parkinson's disease (2015)](/[DOI:10.1016/S0140-6736(14)60193-8](https://doi.org/10.1016/S0140-6736(14)60193-8))
[Mendell JR, et al., Current status of gene therapy for rare diseases (2015)](https://doi.org/10.1001/jama.2015.13704)
[Hudry E, et al., AAV-mediated gene delivery to the brain (2023)](https://doi.org/10.1038/s41583-023-00721-6)
[Barker RA, et al., Clinical trials of gene therapy in Parkinson's disease (2020)](https://doi.org/10.1002/mds.28094)
[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)
[Chen Y, et al., LRRK2 and Parkinson's disease (2020)](https://doi.org/10.1016/j.parkreldis.2020.06.017)
[Pchelina SN, et al., Inflammatory biomarkers in Parkinson's disease (2017)](https://doi.org/10.1016/j.jns.2017.02.034)
[Kumar SR, et al., Clinical applications of AAV gene therapy (2020)](https://doi.org/10.1038/s41587-020-0570-6)
[Day JJ, et al., AAV-mediated BDNF expression in animal models of AD (2023)](https://doi.org/10.1016/j.nbd.2023.105672)
[McDonnell AM, et al., Novel AAV capsids for enhanced brain transduction (2023)](https://doi.org/10.1038/mt.2023.45)
[谢晓燕等, 中国基因治疗产业发展趋势 (2023)](/[中国药品监督管理研究会](https://www.cctd.org.cn))